InMed Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Sep 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 30, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
Consolidated Financial Statements of
For the Years Ended June 30, 2024 and 2023
(Expressed in U.S. Dollars)
June 30, 2024
| INDEX | Page | |
|---|---|---|
| Consolidated Financial Statements | ||
| ● | Report of Independent Registered Public Accounting Firm (PCAOB Firm ID 688) | F-3 |
| ● | Consolidated Balance Sheets | F-4 |
| ● | Consolidated Statements of Operations | F-5 |
| ● | Consolidated Statements of Shareholders’ Equity | F-6 |
| ● | Consolidated Statements of Cash Flows | F-7 |
| ● | Notes to the Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.